Que está pasando @viajaVolaris Culiacán . Sobre vendiendo boletos . Existen personas que trabajamos a primera hora y no nos asignas asiento . Pésimo servicio @Profeco vuelo: Y4391 Culiacán - CDMX
👨🦲62M presents with progressive right-sided ptosis, ophthalmoplegia, and intense supraorbital pain unresponsive to analgesics. Months later, hypoesthesia in V1/V2 distribution appears. History of multiple facial skin tumors.
❔What could be causing his cavernous sinus syndrome?
The tremendous impact of SRS for brain metastases is felt everyday for our patients. Left image showing one of many lesions but this one affecting the midbrain and thalamus. Right image showing substantial response within 2 months. Patient doing great!
Hoy quiero reflexionar sobre una inquietud que muchos de nosotros hemos compartido en algún momento: ¿Por qué, en muchos contextos, parece que se premia la mediocridad ?
🚨 Should RT Dose Be Personalized in NSCLC with Actionable Mutations?@OncoAlert
A real-world multicenter study explores dose escalation in EGFR/ALK+ 👥
🎯 Objective
•Investigate if standard RT doses are sufficient for NSCLC 👥 w/ EGFR/ALK mutations, given their unique tumor biology
🏥 Methods
•Multicenter retrospective study
•Patients: NSCLC Stage III w/ actionable mutations
•☢️Dose: Standard (60-66 Gy) vs. escalated dose
•🎯: Local control, OS & toxicity
📊 Key Findings
•Standard dose may be suboptimal for EGFR/ALK+ tumors
•Dose escalation 🔛 to improved local control
•N🚫 significant ⬆️ in toxicity
Adjuvant therapies in Pancreatic Cancer.
Folfirinox (PRODIGE24)
✅ OS 54 v 35m ✅ mDFS 21 v 12m
Gem Cap (ESPAC4)
OS ✅ 28 vs 25m DFS ❌
Gem Nabpacli (APACT)
OS ✅ 40 v 36m, DFS ❌
Radiation (LAP07) ❌
What is routinely used in practice?
@SuyogCancer@OncBrothers
Guiding Treatment for Patients With Prostate Cancer With Biochemical Recurrence After Prostatectomy
https://t.co/2TF9uZEFk7
with @AmarUKishan@DrSpratticus
Thanks @ASCO Daily News
Related @NatRevUrol article: https://t.co/AFzrHLoEYW
https://t.co/kfBMkjK6lD